UPI (MM)

MINNEAPOLIS, Sept. 28 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that CIGNA Government Services, Palmetto GBA for Ohio and West Virginia, and Pinnacle Business Solutions, Inc., all regional Medicare carriers, now cover posterior tibial nerve stimulation (PTNS) using the Urgent® PC Neuromodulation System for the treatment of the symptoms of overactive bladder.  CIGNA Government Services currently administers benefits for Medicare beneficiaries in Idaho and North Carolina.  The Palmetto GBA coverage extends to Medicare beneficiaries of Ohio and West Virginia, in addition to previously announced coverage in South Carolina.  Pinnacle Business Solutions, Inc. currently covers Medicare beneficiaries in Arkansas and Louisiana.

All three regional Medicare carriers will cover PTNS therapy for patients who have failed, or demonstrated intolerance to, standard anticholinergic drug therapy.  Coverage by CIGNA Government Services and Palmetto GBA, Ohio and West Virginia includes an initial course of 12 weekly PTNS treatments, and, for those patients who respond to the initial treatments, additional treatments once every three weeks for up to one year.  Coverage by Pinnacle Business Solutions, Inc. includes a course of 12 weekly treatments.  Claims for PTNS treatments can be submitted electronically using the unlisted CPT® code 64999.  In addition, CIGNA Government Services will reimburse, when medical necessity is met, up to three physician consultations to evaluate and manage treatments during the initial course of PTNS therapy.

These carriers are in addition to the coverage initiated by Noridian Administrative Services, LLC and Palmetto GBA, South Carolina, two regional Medicare carriers that the Company announced in August.  Noridian administers benefits for Medicare beneficiaries in North and South Dakota, Montana, Wyoming, Utah and Arizona.  As previously mentioned, the Palmetto GBA policy covers Medicare beneficiaries in South Carolina.

"It is very encouraging that coverage of PTNS treatments using our Urgent PC Neuromodulation System has been expanded to include three additional regional Medicare carriers," said David Kaysen, President and CEO of Uroplasty, Inc.  "This success reflects the effort by our field based reimbursement managers working with the medical directors of these carriers. These regional Medicare carriers, as part of their analysis of PTNS, reviewed our strong clinical data and determined that PTNS treatments should be considered medically necessary for the beneficiaries within their coverage areas.  We continue to meet with medical directors of other Medicare carriers and private payers to present our strong clinical data and encourage them to cover and reimburse PTNS treatments."

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10'K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

SOURCE Uroplasty, Inc.